ElizabethGTrehuMD

Oncology • Cambridge, MA

Chief Medical Officer

Join to view full profile

Dr. Trehu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Trehu's full profile

Already have an account?

Office
55 Cambridge Pkwy
Cambridge, MA 02142
Phone+1 617-761-8691

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
Inova Fairfax Medical CampusResidency, Internal Medicine, 1988 - 1989
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1985 - 1988
New York University School of MedicineClass of 1985

Certifications & Licensure

MA State Medical License 1990 - 2023

Clinical Trials

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies Start of enrollment: 2018 Dec 06
Completed
Phase 1

Publications & Presentations

PubMed

25 citations
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski
Clinical Cancer Research. 2022-09-01
70 citations
Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy
Bernt van den Blink, Marlous R. Dillingh, Leo C. Ginns, Lake Morrison, Matthijs Moerland
The European Respiratory Journal. 2016-03-01
1 citations
Hillmen Trial of Alemtuzumab in First-Line Chronic Lymphocytic Leukemia Still Provides Valuable Information
Cynthia A. Sirard, Elizabeth G. Trehu
Journal of Clinical Oncology. 2008-05-10

Press Mentions

Jounce Therapeutics to Present Data from Its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual MeetingFebruary 27th, 2019
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual MeetingNovember 10th, 2018
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial ResultsNovember 8th, 2018
Join now to see all

Grant Support

Phase III Comparison Hepatic Therapeutic Embolization VS Arterial ChemotherapyNational Center For Research Resources1995–1997
Phase I Trial Of Verapamil And Chemoembolization In Hepatocellular CarcinomaNational Center For Research Resources1995–1996